PharmX TechnologiesASX:PHX 40 PB Ratio is 5.00 as of Jun. 26, 2026, which is 303% above its 10-year median of 1.24. GuruFocus rates ASX:PHX with a GF Score™ of 40/100 and a GF Value™ of A$0.07 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 611 Healthcare Providers & Services companies, PharmX Technologies ranks worse than 81.51% on this metric.
The historical rank and industry rank for PharmX Technologies's PB Ratio or its related term are showing as below:
ASX:PHX'
s PB Ratio Range Over the Past 10 Years
Min: 0.4 Med: 1.24 Max: 5.74
Current: 5
During the past 13 years, PharmX Technologies's highest PB Ratio was 5.74. The lowest was 0.40. And the median was 1.24.
ASX:PHX's PB Ratio is ranked worse than 81.51% of 611
companies
in the Healthcare Providers & Services industry
Industry Median: 1.98
vs ASX:PHX: 5.00
During the past 12 months, PharmX Technologies's average Book Value Per Share Growth Rate was -3.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -4.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -9.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of PharmX Technologies was 78.00% per year. The lowest was -76.10% per year. And the median was -11.15% per year.
Back to Basics: PB Ratio
PharmX Technologies (ASX:PHX) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PharmX Technologies PB Ratio Related Terms
PharmX Technologies PB Ratio Historical Data
* Premium members only.
The historical data trend for PharmX Technologies's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, PharmX Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmX Technologies PB Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PharmX Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where PharmX Technologies's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PharmX Technologies (ASX:PHX) has a PB Ratio of 5.00 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmX Technologies and its competitors. This is 303% above median its historical median of 1.24. Over the past decade, PharmX Technologies' PB Ratio has ranged from 0.40 to 5.74. According to the industry distribution chart, PharmX Technologies ranks #498 out of 611 companies in the Healthcare Providers & Services industry, placing it in the top 81.5%.
Is PharmX Technologies' PB Ratio too high?
PharmX Technologies' current PB Ratio of 5.00 is 303% above median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.40 to a high of 5.74. The Healthcare Providers & Services industry median PB Ratio is 1.98. PharmX Technologies' value of 5.00 is 152.5% above this industry median. Based on the distribution chart, PharmX Technologies ranks #498 out of 611 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, PharmX Technologies has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmX Technologies' PB Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, PharmX Technologies ranks #498 out of 611 companies for PB Ratio. This places PharmX Technologies in the lower half of its industry. The industry median PB Ratio is 1.98. PharmX Technologies' value of 5.00 is 152.5% above this benchmark. Historically, PharmX Technologies' own PB Ratio has ranged from 0.40 to 5.74 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 1.98, PharmX Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Healthcare Providers & Services company?
The median PB Ratio among Healthcare Providers & Services companies is 1.98, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmX Technologies's current PB Ratio of 5.00 is 152.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmX Technologies and its competitors. For the Healthcare Providers & Services industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmX Technologies's current PB Ratio is 5.00, which is 303% above median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmX Technologies stock overvalued right now?
Based on GuruFocus' analysis, PharmX Technologies (ASX:PHX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.07, compared to a current price of A$0.13 — trading 85.7% above its estimated fair value. The current PB Ratio is 5.00, which is 303% above median its 10-year median of 1.24 and 152.5% above the Healthcare Providers & Services industry median of 1.98. PharmX Technologies' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PharmX Technologies (ASX:PHX), the current PB Ratio is 5.00 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmX Technologies (ASX:PHX) Overvalued in 2026?
Based on GuruFocus' analysis, PharmX Technologies stock appears to be overvalued.
The current stock price of A$0.13 is trading 85.7% above its estimated GF Value™ of A$0.07.
GuruFocus considers PharmX Technologies to be Significantly Overvalued.
Key valuation signals for ASX:PHX:
PB Ratio: 5.00 (303% above median its 10-year median of 1.24)
GF Value™: A$0.07 vs. price of A$0.13 (85.7% above fair value)
Industry Position: 152.5% above the Healthcare Providers & Services median (#498 of 611)
No single metric tells the full story. See the ASX:PHX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmX Technologies Ltd is an Australia-based software and technology company. The company has a single segment which is Health Services. In Health services, the company develops and distributes business software for the pharmacy industry with particular emphasis on point-of-sale and pharmaceutical dispensing software, support services, and associated computer hardware. It derives a majority of its revenue from the Health services business.
40GF Score
Get the complete analysis for ASX:PHX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PHX has been successfully added to your 
